Release date- 30082019 - WALTHAM - Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral
integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present a corporate overview at the Wells Fargo Securities2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05pm ET, in Boston.
Through their partnership, Morphic and Schrodinger have accelerated the discovery and design of potent and selective
integrin inhibitors and activators targeting serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Protagonist Therapeutics announced results from the initial single ascending dose part of the Phase 1 study of PN-943, an oral, gut-restricted alpha-4-beta-7
integrin specific antagonist in development for the potential treatment of inflammatory bowel disease.
Morphic Therapeutic, a biotechnology company developing oral
integrin therapies, has signed a research and development collaboration with United States-based Janssen Biotech, it was reported on Friday.
The researchers found that specialised white blood cells called regulatory T cells from Crohn's patients produced less of a gut-specific protein called
integrin EAA4EAA7 than regulatory T cells from healthy people.
Global Banking News-October 19, 2018-AbbVie & Morphic partnership to develop oral
integrin drugs targeting fibrotic diseases
(EA Pharma) have revealed a mechanism in which an analogue (ER-464195-01) of Eisai's in-house discovered E6007 inhibits
integrin activation by dissociating interaction between calreticulin (CRT) and
integrin alpha 4 (ITGA4), suppressing adhesion and infiltration of leukocytes overall.
Later, at the Trochophore stage (24 hpf), [beta]1-like
integrin was detectable in the developing stomach area.
(3) Moreover, some studies showed that the adhesion capacity of highly metastatic cells could be reduced by inhibiting
integrin expression or modifies the process that leads metastatic cells to anoikis, which is programmed cell death that is induced upon cell detachment from ECM.